SCHEMBL25319633

SCHEMBL25319633

Brc1ccccc1OCc1ccccn1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 2/20 0.56
MAPT P10636 2/20 0.56
HPGD P15428 1/20 0.56
HTR1A P08908 2/20 0.55
ABCB1 P08183 1/20 0.55
DRD2 P14416 1/20 0.55
SYK P43405 10/20 0.54
GRM4 Q14833 1/20 0.53
AURKB Q96GD4 3/20 0.53
INCENP Q9NQS7 3/20 0.53
ADRA2A P08913 1/20 0.51
ADRA2B P18089 1/20 0.51
ADRA2C P18825 1/20 0.51
SMN1; SMN2 Q16637 2/20 0.49
LMNA P02545 1/20 0.49
NPC1 O15118 1/20 0.47
KDM4E B2RXH2 2/20 0.46
ALDH1A1 P00352 1/20 0.46
CYP1A2 P05177 1/20 0.45
CYP3A4 P08684 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12162572 0.80 SLC6A4 (0.57) RAB9AMAPTHPGDHTR1AABCB1
SCHEMBL21801177 0.80 SYK (0.65) RAB9AHTR1AABCB1DRD2SYK
SCHEMBL30418203 0.80 KDM4E (0.45) RAB9AMAPTHPGDHTR1AABCB1
SCHEMBL30697237 0.80 SYK (0.49) RAB9AMAPTHPGDHTR1AABCB1
SCHEMBL22711487 0.80 SYK (0.49) RAB9AMAPTHPGDHTR1AABCB1
SCHEMBL30697123 0.80 SYK (0.49) RAB9AMAPTHPGDHTR1AABCB1
SCHEMBL12100564 0.79 SYK (0.69) RAB9AHTR1AABCB1DRD2SYK
SCHEMBL21465846 0.78 SYK (0.58) HTR1AABCB1DRD2SYKAURKB
SCHEMBL10855730 0.78 ABCB1 (0.55) MAPTHPGDHTR1AABCB1DRD2
SCHEMBL4569960 0.78 SYK (0.59) HTR1AABCB1DRD2SYKAURKB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4680226-A2 ACYLSULFONAMIDE KAT6A INHIBITORS Olema Pharmaceuticals, Inc. (US) 2026-01-21 EP disclosed
US-20260015327-A1 ACYLSULFONAMIDE KAT6A INHIBITORS OLEMA PHARMACEUTICALS INC (US) 2026-01-15 US disclosed
US-12428379-B2 Acylsulfonamide KAT6A inhibitors OLEMA PHARMACEUTICALS, INC. (US) 2025-09-30 US disclosed
US-20250136553-A1 ACYLSULFONAMIDE KAT6A INHIBITORS OLEMA PHARMACEUTICALS, INC. 2025-05-01 US disclosed
US-20250059204-A1 FUSED BENZOISOXAZOLYL COMPOUNDS AS KAT6A INHIBITORS AURIGENE ONCOLOGY LIMITED (IN) 2025-02-20 US disclosed
EP-4448109-A1 FUSED BENZOISOXAZOLYL COMPOUNDS AS KAT6A INHIBITORS Aurigene Oncology Limited (IN) 2024-10-23 EP disclosed
WO-2024189598-A2 ACYLSULFONAMIDE KAT6A INHIBITORS OLEMA PHARMACEUTICALS, INC. (US) 2024-09-19 WO disclosed
WO-2023114710-A1 FUSED BENZOISOXAZOLYL COMPOUNDS AS KAT6A INHIBITORS AURIGENE ONCOLOGY LIMITED (IN) 2023-06-22 WO disclosed
WO-2023114710-A1 FUSED BENZOISOXAZOLYL COMPOUNDS AS KAT6A INHIBITORS AURIGENE ONCOLOGY LIMITED (IN) 2023-06-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250136553-A1 ACYLSULFONAMIDE KAT6A INHIBITORS KAT6A, KAT2A, KAT6B RAB9A 1931/4885MAPT 2500/4885HPGD 3121/4885
US-12428379-B2 Acylsulfonamide KAT6A inhibitors KAT6A, KAT2A, KAT6B RAB9A 1931/4885MAPT 2500/4885HPGD 3121/4885
US-20260015327-A1 ACYLSULFONAMIDE KAT6A INHIBITORS KAT6A, KAT2A, KAT6B RAB9A 1307/4885MAPT 3581/4885HPGD 4322/4885
US-20250059204-A1 FUSED BENZOISOXAZOLYL COMPOUNDS AS KAT6A INHIBITORS KAT6A, KAT2A, KAT6B RAB9A 2582/4885MAPT 196/4885HPGD 3729/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.